Synairgen plc

LSE SNG.L

Synairgen plc EBITDA for the year ending December 31, 2023: USD -12.18 M

Synairgen plc EBITDA is USD -12.18 M for the year ending December 31, 2023, a 49.59% change year over year. EBITDA means earnings before interest, taxes, depreciation, and amortization, which measures a company's operating performance by excluding non-operating expenses.

Synairgen plc EBITDA for the year ending December 31, 2022 was USD -24.16 M, a 69.04% change year over year.
Synairgen plc EBITDA for the year ending December 31, 2021 was USD -78.03 M, a -227.21% change year over year.
Synairgen plc EBITDA for the year ending December 31, 2020 was USD -23.85 M, a -289.21% change year over year.
Synairgen plc EBITDA for the year ending December 31, 2019 was USD -6.13 M, a -17.53% change year over year.

Key data

Date	EBITDA	Net Income	EPS (Diluted)	Shares (Diluted, Weighted)

LSE: SNG.L

Synairgen plc

CEO	Mr. Richard Marsden
IPO Date	Oct. 26, 2004
Location	United Kingdom
Headquarters	Mailpoint 810
Employees	36
Sector	Health Care
Industries Pharmaceuticals Biotechnology

Description

Synairgen plc discovers and develops drugs for respiratory diseases. It develops SNG001, an inhaled interferon beta for the treatment of COVID-19; inhaled interferon beta (IFN-ß), which is in Phase-II clinical trials for the treatment of asthma caused by the common cold and flu; IFN-ß that is in Phase-II clinical trials for the treatment or prevention of chronic obstructive pulmonary disease; and LOXL2 inhibitor for the treatment of idiopathic pulmonary fibrosis (IPF) disease. The company has a licensing and collaboration agreement with Pharmaxis Ltd. to develop a LOXL2 inhibitor. Synairgen plc was incorporated in 2004 and is headquartered in Southampton, the United Kingdom.

Key trends

Past 5 years